2023-504900-28-00撤回2 期
A Phase 1/2 Clinical Study of Intravenous Gene Transfer with an AAVrh10 Vector Expressing GALC in Krabbe Subjects Receiving Hematopoietic Stem Cell Transplantation (RESKUE)
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 入组人数
- 2
- 试验地点
- 1
- 主要终点
- Incidence and severity of adverse events and serious adverse events that are attributed to FBX-101
研究概览
简要总结
The primary objective of this clinical trial is to show that the investigational product, AAVrh.10-hGALC, is safe for administration to infantile Krabbe subjects when delivered intravenously 21 to 60 days following stem cell transplant.
入排标准
- 年龄范围
- 0 years 至 17 years（0-17 Years）
- 接受健康志愿者
- 是
入选标准
- •Diagnosis of infantile Krabbe disease, characterized by the following criteria: a. Galactocerebrosidase (GALC) activity levels in leukocytes compatible with the diagnosis of Krabbe disease; AND AT LEAST ONE OF THE FOLLOWING: b. Elevated psychosine levels predictive of infantile onset by DBS; OR c. Imaging or neurophysiological findings consistent with Krabbe disease (CSF, MRI, NCV, ABR, refer to Addendum 1); OR, d. Two GALC mutations predictive to result in infantile onset phenotype
- •Age at the time of screening: 1 day to 12 months
- •Participant has been deemed eligible for treatment with HSCT (standard of care) and a fully myeloablative reduced intensity/toxicity conditioning regimen (RIC/RTC) is/has been used
- •Participant’s parents or legal guardian consents to participate in the study and provides informed consent according to IRB guidelines prior to any study procedures being performed
- •Parent(s) and/or legal guardian able to comply with the clinical protocol
- •Participant must have adequate organ function at time of screening or evaluation as measured by: a. Creatinine ≤1.5× of upper limit of age appropriate normal and creatinine clearance ≥ 60 mL/min/1.73 m2; b. Hepatic transaminases (ALT/AST) ≤ 2 x age related upper limit of normal; c. Ejection fraction of > 50% by echocardiogram or other appropriate study without evidence of pulmonary hypertension; d. Pulmonary evaluation testing demonstrating resting pulse oximeter > 95% on room air; e. Coagulation tests within 110% of normal ranges for age. (PT/INR and PTT)
排除标准
- •History of prior treatment with a gene therapy product
- •Any other medical condition, serious intercurrent illness, or extenuating circumstance that, in the opinion of the PI, would preclude participation in the study
- •Ongoing veno-occlusive disease (VOD) as determined by liver ultrasound (moderate ascites and static or retrograde portal vein flow) the day before FBX-101 infusion
- •Presence of major congenital anomaly or any other condition that affects neurodevelopmental function
- •Presence of any neurocognitive deficit or brain damage not attributable to Krabbe disease
- •Active aspiration
- •Signs of active infection or disease from cytomegalovirus, adenovirus or other viruses
- •HIV positive
- •Uncontrolled and progressive bacterial or fungal infection
- •Presence of any contraindication for MRI
- •Use of any investigational product prior to study enrollment or current enrollment in another study that involves clinical interventions
结局指标
主要结局
Incidence and severity of adverse events and serious adverse events that are attributed to FBX-101
Incidence and severity of adverse events and serious adverse events that are attributed to FBX-101
HSCT incident of engraftment
HSCT incident of engraftment
次要结局
- Improvement of probability to achieve independent sitting compared to untreated patients or those receiving HSCT only at one year and two years post gene therapy
- Improvement of gross motor function, as measured by Peabody Developmental Motor Scale 2nd Edition (PDMS-2), above a functional age equivalent of 12 months, compared to untreated patients or those receiving HSCT only, at 2 years post gene therapy
研究者
Maria Escolar
Scientific
Forge Biologics Inc.
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
Gene Transfer Clinical Trial for Krabbe DiseaseKrabbe DiseaseNCT04693598Forge Biologics, Inc6
招募中
1 期
A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)FTD-GRNDementia, FrontotemporalFrontotemporal DementiaFTDNCT06064890AviadoBio Ltd18
已完成
1 期
CEA-Expressing Liver Metastases Safety Study of Intrahepatic Infusions of Anti-CEA Designer T CellsLiver MetastasesNCT01373047Roger Williams Medical Center8
招募中
1 期
Phase IA and IB Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich's AtaxiaCardiomyopathiesCardiac HypertrophyMyocardial FibrosisFriedreich AtaxiaNCT05302271Weill Medical College of Cornell University25
进行中（未招募）
1 期
Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine TherapyBreast CancerBreast CarcinomaMalignant Neoplasm of BreastNCT02204098Washington University School of Medicine27